NCT07274345Not yet recruiting
Prevalence and Risk Factors of Antiviral Resistance in Egyptian HBV Patients
Prevalence and Risk Factors Associated With Resistance to Antiviral Therapy in Egyptian Patients With Chronic Hepatitis B Virus Infection
Source: ClinicalTrials.gov · Last updated 10 Dec 2025
Brief summary (registry, in English)
This study aims to determine the prevalence of antiviral drug resistance among Egyptian patients with chronic hepatitis B virus (HBV) infection and to identify the associated demographic, clinical, and virological risk factors. Understanding patterns of resistance will help improve treatment selection and optimize long-term management strategies for HBV patients.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 2000 (estimated)
- First submitted
- 27 Nov 2025
- Start date
- 1 Dec 2025
- Primary completion date
- 1 Jun 2026
- Lead sponsor
- Amira Mohamed Zidan
- Diseases
- Hepatitis B
- NCT number
- NCT07274345
What you commit to
- Study type: Observational
- Planned participants: 2000
- From 1 Dec 2025 to the primary completion date, 1 Jun 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Patients younger than 18 years old.
Who the study is looking for
- This study will include all chronic HBV-infected patients, either cirrhotic or not, receiving TDF 300 mg, ETV 0.5 or 1mg, or lamivudine 100 mg, irrespective of HBeAg status. The HBV chronicity is defined by persistence of HbsAg positivity for more than 6 months.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.